Skip to main content
OpenTrials
Completed

NCT Number: NCT03097835

Evaluation of Skin Quality Improvement

The purpose of this study is to comprehensively investigate and objectively demonstrate the effectiveness of hyperdiltue Botox® Cosmetic in improving overall skin quality, more specifically evenness of skin tone, reduction of pore size and improvement in the appearance of preexisting skin scars.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Quality

Age range

35 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Steve Yoelin MD & Associates

Newport Beach, California, 92663, United States

About this study

The purpose of this study is to comprehensively investigate and objectively demonstrate the effectiveness of hyperdiltue Botox® Cosmetic in improving overall skin quality, more specifically evenness of skin tone, reduction of pore size and improvement in the appearance of preexisting skin scars. The ability of hyperdilute Botox® Cosmetic to improve overall skin quality is likely optimized when it is injected uniformly in hyper-diluted small aliquots in order to "saturate" the dermis. We propose to prepare Botox® Cosmetic in a manner that is approximately 4 times more dilute compared to the typical Botox® Cosmetic preparation. A 4x4 centimeter area located in the mid-cheek adjacent to the nose will be injected with hyperdilute Botox® Cosmetic. Botox® Cosmetic is not FDA-approved for this use. A maximum of 15 subjects will participate in this study, all of whom will receive injections of Botox® Cosmetic during the course of this study.

This study is a randomized, placebo-controlled, and double-masked study. This means neither the study doctor nor participant know the experimental agent (e.g., 0.9% saline solution and hyperdiluted Botox® Cosmetic) injected on each side of the patients' faces. The study will last for a total of 75 days. Evaluation of the study is based on the analysis of photographic images obtained during the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to follow study instructions and likely to complete all required visits
  • Written consent has been obtained
  • Written authorization for "Use and Release of Health and Research Study Information" has been obtained
  • Subjects who are Fitzpatrick Skin Types II-IV

Exclusion criteria

  • Subjects must be Onabotulinum Toxin Type A naive; if subject has had Onabotulinum Toxin Type A administered in the face in the previous 12 months they are excluded
  • Subjects must be dermal filler naïve in the lateral canthal region and midface regions
  • Subjects must be energy or light device naïve
  • Subjects must have average or below-average lifetime sun exposure
  • Subjects must be free of inflammatory skin disease(s)

Treatment and study plan

Hyper-Diluted Botox

Drug

0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½" needle

Topical anesthesia

Drug

Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes

0.9% saline solution

Other

0.1ml of 0.9% saline solution will be administered to the side of the face

Primary outcomes

  1. Percent Improvement in Skin Quality

    Time frame: Entire duration of the study (Day 1-Day 135)

    An evaluation of the percent improvement in skin quality when the "Onabotulinum Toxin Type A" treated side of face is compared to the "placebo" treated side of the face. Good skin quality is defined as small pore size, evenness of skin texture, evenness of skin tone, minimal presence of wrinkles, and minimal presence of scars. We will measure improvement primarily by image analysis of the photos taken during each visit using the Canfield Scientific camera (or the Allergan provided alternative).

Secondary outcomes

  1. Patient and Investigator Reported Outcomes

    Time frame: Entire duration of the study (Day 1-Day 135)

    An objective observer as well as the patient will evaluate if there is an improvement in skin quality throughout the course of the study.

Sponsors and collaborators

Lead sponsor

Steve Yoelin M.D. Medical Associates, Inc.

Other

Collaborators

  • Allergan

Registry information

Official study title

Evaluation of Skin Quality Improvement When Hyper-Diluted OnabotulinumtoxinA (Botox®, Botox® Cosmetic /BTXa/) is Injected Into The Superficial Dermis of the Mid-Face

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Mar 31, 2017
Registry last updated
Feb 22, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.